Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Molecular correlates of vaccine-induced protection against typhoid fever.

Zhu H. et al, (2023), J Clin Invest, 133

Distinct glycosylation and functional profile of typhoid vaccine-induced antibodies in a UK challenge study and Nepalese children.

HILL J. et al, (2022), Frontiers in Analytical Science

Genetic Susceptibility to Enteric Fever in Experimentally Challenged Human Volunteers.

Barton A. et al, (2022), Infect Immun, 90

Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.

Shakya M. et al, (2021), Lancet Glob Health, 9, e1561 - e1568

Persistence of Antibody After a Vi-Tetanus Toxoid Conjugate Vaccine and Effect of Boosting With a Plain Polysaccharide Vaccine on Vi Antibody and Antigen-Specific B Cells

Bentley T. et al, (2021), Frontiers in Tropical Diseases, 2

Association of Antibody-Dependent Neutrophil Phagocytosis With Distinct Antibody Glycosylation Profiles Following Typhoid Vaccination

Johnson M. et al, (2021), Frontiers in Tropical Diseases, 2

A Salmonella Typhi Controlled Human Infection Study for Assessing Correlation between Bactericidal Antibodies and Protection against Infection Induced by Typhoid Vaccination.

Jones E. et al, (2021), Microorganisms, 9

Vi-specific serological correlates of protection for typhoid fever.

Jin C. et al, (2021), J Exp Med, 218

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply.

Voysey M. and Pollard AJ., (2020), Lancet, 396, 1486 - 1487

Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomised controlled human infection model.

Gibani MM. et al, (2020), PLoS Negl Trop Dis, 14

Evaluation of a standardised Vi poly-l-lysine ELISA for serology of Vi capsular polysaccharide antibodies.

Rigsby P. et al, (2020), Biologicals, 66, 21 - 29

Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever.

Cross DL. et al, (2020), Front Immunol, 11

Investigation of the role of typhoid toxin in acute typhoid fever in a human challenge model.

Gibani MM. et al, (2019), Nat Med, 25, 1082 - 1088

The Impact of Vaccination and Prior Exposure on Stool Shedding of Salmonella Typhi and Salmonella Paratyphi in 6 Controlled Human Infection Studies.

Gibani MM. et al, (2019), Clin Infect Dis, 68, 1265 - 1273

IgA and IgG1 Specific to Vi Polysaccharide of Salmonella Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model.

Dahora LC. et al, (2019), Front Immunol, 10

Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.

Jin C. et al, (2017), Lancet, 390, 2472 - 2480

Salmonella Typhi Bactericidal Antibodies Reduce Disease Severity but Do Not Protect against Typhoid Fever in a Controlled Human Infection Model.

Juel HB. et al, (2017), Front Immunol, 8

Natural and Vaccine-Mediated Immunity to Salmonella Typhimurium is Impaired by the Helminth Nippostrongylus brasiliensis

Bobat S. et al, (2014), PLoS Neglected Tropical Diseases, 8

Include forthcoming?